Variant position: 168 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 894 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human IKRGLASLFQTQLSSGTTNE VDISGNCKVTYQAHQDKVIKI
Mouse LKRGLASLFQMQLSSGTTNE VDISGDCKVTYQAQQDKVVKI
Rat LKRGLASLFQMQLTSGTTNE VDISGDCKVTYQAQQDKVVKI
Pig LKRGLASLFQMQLSSGTTNE VDISGDCKVTYQAHQDKVTKI
Zebrafish LKRGVASMLMMQLKSGKMSE ADASGKCLVEYKVNKHQVIRT
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
19 – 894 Microsomal triglyceride transfer protein large subunit
28 – 659 Vitellogenin
152 – 894 Missing. In isoform 2.
169 – 169 D -> E. No loss on localization to the endoplasmic reticulum and does not reduce interaction with APOB or P4HB/PDI, does partially reduce phospholipid or triglyceride transfer activity and apolipoprotein B secretion.
187 – 187 K -> L. No loss on localization to the endoplasmic reticulum and does not reduce interaction with APOB, but inhibits interaction with P4HB/PDI, phospholipid or triglyceride transfer activity and apolipoprotein B secretion.
187 – 187 K -> R. No loss on localization to the endoplasmic reticulum, does not reduce interaction with APOB or P4HB/PDI, partially inhibits triglyceride transfer activity, does not inhibit phospholipid transfer activity and apolipoprotein B secretion.
Hypobetalipoproteinemia with an apparently recessive inheritance due to a 'de novo' mutation of apolipoprotein B.
Lancellotti S.; Di Leo E.; Penacchioni J.Y.; Balli F.; Viola L.; Bertolini S.; Calandra S.; Tarugi P.;
Biochim. Biophys. Acta 1688:61-67(2004)
Cited for: VARIANTS THR-128; ILE-168 AND GLN-297;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.